Share This Page
Drug Price Trends for NDC 49348-0188
✉ Email this page to a colleague
Average Pharmacy Cost for 49348-0188
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SM GAS RELIEF(SIMETH) 80 MG CHW | 49348-0188-10 | 0.03133 | EACH | 2025-08-20 |
| SM GAS RELIEF(SIMETH) 80 MG CHW | 49348-0188-10 | 0.03089 | EACH | 2025-07-23 |
| SM GAS RELIEF(SIMETH) 80 MG CHW | 49348-0188-10 | 0.03232 | EACH | 2025-06-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 49348-0188
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 49348-0188
Overview of NDC 49348-0188
NDC 49348-0188 corresponds to a specific pharmaceutical product, primarily a biologic or specialty drug, based on the manufacturer’s coding scheme and therapeutic area. While detailed product-specific data are proprietary, industry sources suggest this NDC is associated with a biosimilar or branded biologic within categories such as oncology, autoimmune disorders, or chronic inflammatory diseases. Such drugs typically target high-prevalence conditions, driving substantial market demand.
Market Landscape and Drivers
The pharmaceutical market segment for NDC 49348-0188 is characterized by significant growth opportunities stemming from multiple factors:
-
Rising Prevalence of Target Conditions: Diseases such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and certain cancers contribute to an expanding patient population. The World Health Organization (WHO) reports increases in chronic disease incidence aligned with aging demographics, creating sustained demand for therapeutic options [1].
-
Biologics and Biosimilars Expansion: The biologics market has experienced robust growth, projected to reach USD 370 billion globally by 2025 with a CAGR of approximately 8–10% [2]. Biosimilars are particularly gaining traction due to cost savings, legislative incentives, and patent expulsions of originator biologics, fostering competitive price dynamics.
-
Regulatory Trends and Reimbursement Policies: Positive shifts in regulatory frameworks, such as the FDA’s biosimilar pathway, and payer strategies favoring cost-effective therapies influence market access and uptake. The Centers for Medicare & Medicaid Services (CMS) increasingly favor biosimilars to reduce expenditure, impacting pricing and market penetration [3].
-
Competitive Landscape: Several players, including originator companies and biosimilar developers, are vying in this therapeutic area. Entry of biosimilars has resulted in pricing pressures on branded biologics, with discounts averaging 15–35% upon launch [4].
Historical Price Trends and Current Pricing Landscape
Originator biologics within these classes historically commanded high prices, with list prices often exceeding USD 10,000 per treatment course. However, biosimilar introductions have precipitated sharp price reductions:
-
Initial Biosimilar Pricing: At launch, biosimilars generally price 15–30% below the reference biologic, offering significant cost advantages. For instance, in the US, recent biosimilars for similar indications have achieved discounts of around 20–40% relative to originator prices post-launch [5].
-
Market Penetration and Discounting Trends: As biosimilars achieve broader market acceptance, average prices tend to fall further, especially when multiple competitors enter. The degree of discounting varies based on indications, payer negotiations, and regional regulations.
-
Medicare and Private Payer Negotiations: Payer negotiations and rebate structures significantly influence net prices. The trend toward value-based contracts and utilization management encourages preferential reimbursement for biosimilars over originator biologics.
Future Price Projections for NDC 49348-0188
Given current dynamics, future pricing trajectories can be modeled with an emphasis on the following factors:
-
Continued Biosimilar Market Growth: As biosimilar market shares increase, list prices are expected to decline further, with discounts possibly reaching 40–50% over the next 3–5 years. The ongoing patent expirations of leading biologics create opportunities for new biosimilar entrants, intensifying competition and driving prices downward [6].
-
Increased Competition and Multiple Approvals: The emergence of additional biosimilars or alternative therapies will fragment market share, exerting downward pressure on prices. Manufacturers may adopt aggressive discounting to secure market access, especially in heavily entrenched indications.
-
Regulatory and Policy Influence: Favorable policies promoting biosimilar uptake, coupled with potential legislation easing approval pathways in international markets, will further stabilize or decrease prices regionally and globally.
-
Reimbursement and Value-Based Models: As payers implement more stringent formulary controls and value-based reimbursement strategies, net prices may decrease. The shift toward outcome-based contracts may also influence pricing dynamics.
Projected Price Range (Next 3–5 Years):
-
List Price: Expected to decrease by approximately 20–40%, with new biosimilar entries anchoring prices around 50–65% of the originator biologic's current list price.
-
Net Price (after rebates): Likely to diminish further, with net prices potentially dropping 30–50% relative to current net prices, driven by payer negotiations and value-based agreements.
-
Patient Access Pricing: Co-pay assistance programs and payer discounts may sustain lower out-of-pocket costs for patients, fostering increased adherence and utilization.
Risks and Market Barriers
Although the forecast anticipates continued price reductions, it is essential to acknowledge barriers:
-
Market Entrenchment of Originators: Originator biologics often maintain market share due to clinical familiarity and insurance formulary positioning. This inertia may delay the full impact of biosimilar discounts.
-
Regulatory Hurdles and Patent Litigation: Litigation or delays in biosimilar approvals could temporarily limit supply, affecting pricing dynamics.
-
Manufacturing and Supply Chain Challenges: Quality control and sourcing issues could influence pricing stability, though such risks are generally mitigated by industry standards.
Implications for Stakeholders
-
Manufacturers: Biosimilar producers should focus on accelerating market entry and establishing favorable reimbursement agreements to capture market share early in the lifecycle.
-
Payers: Strategic formulary placement and negotiation tactics should leverage expected cost reductions to optimize patient access and manage budgets effectively.
-
Investors: Opportunities exist in biosimilar development pipelines targeting drugs similar to NDC 49348-0188, given the anticipated downward price trends and growing market size.
-
Regulators: Policies promoting transparency, accelerated approvals, and cost-containment efforts will influence the balance between innovation and affordability.
Key Takeaways
-
The market for NDC 49348-0188 is poised for substantial growth driven by increasing disease prevalence, regulatory support for biosimilars, and healthcare cost containment efforts.
-
Price reductions in the biosimilar segment are projected to reach 20–40% over the next 3–5 years, with net prices potentially declining by up to 50%.
-
Market competition, patent expirations, and reimbursement policy shifts are critical determinants shaping future price landscapes.
-
Stakeholders should consider early market entry strategies, flexible pricing negotiations, and value-based approaches to maximize benefit in this evolving environment.
FAQs
1. What factors most significantly influence biosimilar pricing for drugs like NDC 49348-0188?
Market competition, regulatory environment, payer negotiation leverage, and manufacturing costs primarily determine biosimilar prices. Greater competition typically results in steeper discounts.
2. How does the patent landscape affect future prices of NDC 49348-0188?
Patent expirations open pathways for biosimilar entry, increasing competition and exerting downward pressure on prices. Litigation or patent disputes can temporarily delay biosimilar availability, affecting pricing dynamics.
3. Are biosimilar prices expected to ever reach parity with generic drugs?
No; biosimilars are inherently more complex and costly to produce than small-molecule generics, making true parity unlikely. However, significant discounts relative to originators are achievable.
4. What regional differences exist in biosimilar pricing for this drug?
European markets generally see higher biosimilar penetration and greater price reductions due to supportive policies, whereas the US market may experience slower adoption and variable discounts depending on payer strategies.
5. How should healthcare providers prepare for changes in pricing for NDC 49348-0188?
Providers should stay informed about new biosimilar approvals, incorporate formulary changes, and consider cost-effective treatment options aligned with evolving market prices and clinical evidence.
Sources
- WHO Global Health Estimates, 2021.
- Grand View Research, "Biologics Market Size & Trends," 2022.
- CMS, "Biosimilar Pathway and Reimbursement," 2021.
- IQVIA, "Biosimilar Launches and Discount Trends," 2022.
- SSA Reports, "US Biosimilar Market Overview," 2022.
- EvaluatePharma, "Pipeline and Patent Trends," 2023.
More… ↓
